- Home
- PMCB vs KXIN Comparison
PMCB vs KXIN Comparison
Compare PMCB & KXIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PMCB | KXIN |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | China |
| Employees | N/A | 13 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Retail-Auto Dealers and Gas Stations |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2M | 9.3M |
| IPO Year | 2001 | N/A |
Fundamental Metrics
Financial Performance| Metric | PMCB | KXIN |
|---|---|---|
| Price | $0.83 | $6.05 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 324.8K | ★ 445.9K |
| Earning Date | 03-17-2026 | 11-26-2019 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 277.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.63 | $0.11 |
| 52 Week High | $1.51 | $22.00 |
Technical Indicators
Market Signals| Indicator | PMCB | KXIN |
|---|---|---|
| Relative Strength Index (RSI) | 51.07 | 57.69 |
| Support Level | $0.66 | $5.30 |
| Resistance Level | $0.80 | $6.45 |
| Average True Range (ATR) | 0.09 | 0.51 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 38.47 | 75.90 |
Price Performance
Historical ComparisonAbout PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
About KXIN Kaixin Auto Holdings
Kaixin Holdings is an auto dealership company mainly engaged in the sale of domestic and imported automobiles in China. The company provides new and used car buyers in China with access to a wide selection of used vehicles across its network of dealerships, with a focus on premium brands such as Audi, BMW, Mercedes-Benz, Land Rover, and Porsche. The company generates revenue from automobile sales and related services.